Open Access

All‑trans retinoic acid alters the expression of the tight junction proteins Claudin‑1 and ‑4 and epidermal barrier function‑associated genes in the epidermis

Corrigendum in: /10.3892/ijmm.2024.5399

  • Authors:
    • Jing Li
    • Qianying Li
    • Songmei Geng
  • View Affiliations

  • Published online on: February 15, 2019     https://doi.org/10.3892/ijmm.2019.4098
  • Pages: 1789-1805
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

All‑trans retinoic acid (ATRA) regulates skin cell proliferation and differentiation. ATRA is widely used in the treatment of skin diseases, but results in irritation, dryness and peeling, possibly due to an impaired skin barrier, although the exact mechanisms are unclear. The present study established an ATRA‑associated dermatitis mouse model (n=32) in order to examine the molecular mechanisms of skin barrier impairment by ATRA. Changes in epidermal morphology and structure were observed using histological examination and transmission electron microscopy (TEM). Gene expression was analyzed by microarray chip assay. Histology and TEM demonstrated pronounced epidermal hyperproliferation and parakeratosis upon ATRA application. The stratum corneum layer displayed abnormal lipid droplets and cell‑cell junctions, suggesting alterations in lipid metabolism and dysfunctional cell junctions. Gene expression profiling revealed that factors associated with epidermal barrier function were differentially expressed by ATRA, including those associated with tight junctions (TJs), cornified envelopes, lipids, proteases, protease inhibitors and transcription factors. In the mouse epidermis, Claudin‑1 and ‑4 are proteins involved in TJs and have key roles in epidermal barrier function. ATRA reduced the expression and altered the localization of Claudin‑1 in HaCaT immortalized keratinocytes and the mouse epidermis, which likely leads to the disruption of the epidermal barrier. By contrast, Claudin‑4 was upregulated in HaCaT cells and the mouse epidermis following treatment with ATRA. In conclusion, ATRA exerts a dual effect on epidermal barrier genes: It downregulates the expression of Claudin‑1 and upregulates the expression of Claudin‑4. Claudin‑4 upregulation may be a compensatory response for the disrupted barrier function caused by Claudin‑1 downregulation.

Introduction

All-trans retinoic acid (ATRA) exerts essential roles in reproduction, embryogenesis, cell proliferation, differentiation and apoptosis (1,2). ATRA also regulates skin function and is widely used for the treatment of skin diseases such as acne, psoriasis, ichthyosis and skin cancer (3-5), but its clinical application is limited by adverse skin reactions, including erythema, scaling, dryness, desquamation and vessel dilation. These reactions are potentially associated with epidermal barrier dysfunction (6), but the mechanisms are largely unknown.

Tight junctions (TJs) in epithelial and endothelial tissues have been well studied, and a previous study suggested that the TJs of the stratum granulosum (SG) are responsible for the protective function of epithelial tissues (7). TJs consist of transmembrane Claudins, adherent junction (AJ) molecules, occludin, plaque proteins (e.g. zonula occludens-1, -2 and -3, and multiple PDZ domain protein), and cell polarity complex proteins [e.g. the protein kinase C ι-type/partitioning defective 3 homolog (Par3)/Par6 complex] (8). Claudins contain two extracellular loops (cytoplasmic C- and N-terminal) and four transmembrane domains (9,10). Claudins-1, -2, -4 and -6 are essential for TJ formation and are involved in the barrier to paracellular transport (9,11-14). The roles of Claudins in barrier function have been addressed in epithelial cell cultures and Claudin-knockout/transgenic mice (15,16). Claudin-1 and -4 are concentrated in TJs (17). Continuous Claudin-based TJs are present in the epidermis and these particular TJs are crucial for the barrier function of mammalian skin (17). In addition, Claudin-1 and -4 are involved in the pathogenesis of skin lesions (18-20). How Claudin-1 and -4 are regulated in response to ATRA is largely unknown.

To understand the molecular basis of ATRA-induced barrier dysfunction, a gene expression array was used to observe the differential gene expression in mouse skin and HaCaT cells following treatment with ATRA. Using a mouse model and a gene expression array, it was demonstrated that ATRA does, in fact, alter the structure of TJs in mouse skin. Therefore, the hypothesis was that Claudins possibly exert an essential role in barrier dysfunction during ATRA-induced skin irritation. The present study aimed to investigate the molecular mechanisms of barrier dysfunction during ATRA-induced skin irritation.

Materials and methods

Animals

Male BALB/c mice (n=32; 8 weeks of age; weight, ~25 g) were obtained from Xi’an Jiaotong University Animal Center (Xi’an, China). The mice were fed standard chow and had access to water ad libitum, and were caged in a controlled environment (12 h light/dark cycle; temperature, 20-25°C; humidity, 45-55%). The mice were acclimatized for 3 days prior to any experiments. All experimental procedures were performed in accordance with the ‘Principles of Laboratory Animal Care’ (NIH) and with the approval of the laboratory animal care committee of Xi’an Jiaotong University (no. XJTULAC2017-733).

Animal treatment

The skin on the backs of the mice was shaved using an electric shaver. The mice were divided into two group: i) Treated with topical 0.1% ATRA cream (Chongqing Winbond Pharmaceutical Co., Ltd., Chongqing, China) twice a day; and ii) treated with an oil/water cream (vehicle control) twice a day. The Psoriasis Area and Severity Index (PASI) scoring system was used to assess the severity of inflammation on the back skin of the mice (21). The PASI is widely used in clinical practice. Erythema, scales and thickening are scored as follows: 0, absent; 1, slight; 2, mild; 3, obvious; and 4, very obvious. The sum of the scores of these three factors is an indicator of the severity of inflammation (score of 0-12).

After 5 days of treatment, the mice were anesthetized using pentobarbital at 50 mg/kg. The skin from the backs of the mice, including the dermis and subcutaneous tissues, was removed. The skin was washed with pre-cooled PBS, excess fat was removed, and the specimens were placed in liquid nitrogen for RNA extraction. Subsequently, the mice were sacrificed by cervical dislocation.

Histological and ultrastructural analysis

ATRA-treated and untreated mouse dorsal skin specimens (1×1.5 cm) were fixed in 4% paraformaldehyde for 24 h at 4°C, dehydrated and embedded in paraffin. The samples were sectioned at 7 µm and stained with hematoxylin for 5 min and eosin for 2 min at room temperature. The epidermal thickness, parakeratosis, spongiosis and degree of inflammation were evaluated. Spongiosis (presence of widened intracellular spaces between epidermal keratinocytes) and inflammation were evaluated on a scale of 0-4. Epidermal thickness and spongy edema were measured using the built-in measurement tool in the software ndp.view2 (Hamamatsu Photonics K.K., Hamamatsu, Japan; https://www.hamamatsu.com/jp/en/product/type/U12388-01.html; version 2.7). The expanded capillaries were counted at high magnification (×200) in 10 randomly selected fields under an Olympus BX51 light microscope equipped with a DP70 digital camera (Olympus Corporation, Tokyo, Japan). Incomplete keratinization was assessed as present or absent (22).

The specimens were cut into 1-cm blocks and dipped in ice-cold sodium cacodylate buffer solution containing 2.5% glutaraldehyde at 4°C for 24 h. The blocks were washed three times and treated with 1% osmium tetroxide at 4°C for 1 h. The samples were dehydrated using an ethanol series and embedded in Epon 812. Ultra-thin sections were stained with lead citrate for 10 min and uranyl acetate for 30 min at room temperature. Ultrastructural changes were observed by transmission electron microscopy (TEM) using a H7650 microscope (Hitachi, Ltd., Tokyo, Japan).

Cell culture and treatment

HaCaT cells (immortalized keratinocytes) were obtained from the Fourth Military Medical University (Shan’xi, China) and grown in RPMI-1640 (GE Healthcare, Chicago, IL, USA) with 10% fetal bovine serum (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin (GE Healthcare). Short tandem repeat profiling was performed by Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd. (Shanghai, China) to validate the cell line. The cells were subcultured following dissociation with 0.25% trypsin/0.05% EDTA (1:1) and passaged at a ratio of 1:4 every 3 days.

HaCaT cells (5,000 cells/well) were incubated in 96-well plates for 48 h and treated by different concentrations (0.1, 0.5, 1, 5 and 10 µM) of ATRA at 37°C for a further 36 h. A volume of 20 µl MTT solution (5 mg/ml) was added to each well and the culture continued for 4 h. Subsequently, the medium was removed, and 150ul dimethyl sulfoxide (DMSO) was added to each well. The light absorption value of each well was measured at optical density 490 nm (570 nm) with a micro-plate reader. Following determination of the half-maximal inhibitory concentration using different concentrations of ATRA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), HaCaT cells were incubated with or without 1 µM ATRA for 36 h at 37°C, which was chosen for use in the subsequent experiments. Stock solutions of ATRA (0.01 M) were prepared in DMSO, stored in the dark at −20°C, and further diluted with RPMI-1640. The concentration of DMSO was 1‰.

Microarray analysis

Microarray analysis was used primarily to identify candidates that were later confirmed via reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and/or immunohistochemistry. The gene expression profiles in the skin of mice and in HaCaT cells treated or untreated with ATRA were compared using NimbleGen Gene Expression analysis (Nimblegen Systems Inc., Madison, WI, USA). The ds-cDNA samples were washed and labeled according to the Nimblegen Gene Expression Analysis protocol (Nimblegen Systems Inc.). A NanoDrop ND-1000 was used to quantify the cDNA following purification. Cy3 labeling was conducted using the NimbleGen One-Color DNA labeling kit (NimbleGen Systems, Inc.), according to the manufacturer’s protocol. Subsequently, 100 U Klenow fragment (New England Biolabs, Inc., Ipswich, MA, USA) and 100 pmol deoxynucleoside triphosphates were added and incubated at 37°C for 2 h. One-tenth volume of 0.5 M EDTA was added to stop the reaction. The labeled ds-cDNA was purified using isopropanol/ethanol precipitation. The microarrays were immersed in the NimbleGen hybridization buffer/hybridization component A, which was supplemented with 4 µg ds-cDNA with Cy3 labeling. The reaction system was kept in a hybridization chamber (Nimblegen Systems, Inc.) at 42°C for 4 h. The NimbleGen Wash Buffer kit (Nimblegen Systems, Inc.) was used to wash the microarrays in an environment without ozone. The Axon GenePix 4000B microarray scanner was used to scan the microarrays.

RT-qPCR

The RNAeasy Midi kit (Qiagen AB, Sollentuna, Sweden) was used to isolate the total mRNA, according to the manufacturer’s protocol. RNA (1 µg) was added in a 20-µl reaction system (PrimeScript RT Reagent Kit; Takara, Otsu, Japan) at 37°C for 15 min and 85°C for 5 sec for cDNA synthesis. The SYBR Premix Ex Taq II amplification kit (Perfect Real Time; Takara Biotechnology Co., Ltd., Dalian, China) was used for qPCR on a Bio-Rad IQ5 System (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The conditions were: i) 95°C denaturation for 10 min; and ii) 40 cycles at 95°C for 10 sec and 60°C for 30 sec. The primers are listed in Table I. β-actin was used for normalization. The results were analyzed using the IQ5 software (version 2.5). Gene expression levels were calculated using the 2−ΔΔCq method (23).

Table I

Primers for reverse transcription-quantitative polymerase chain reaction.

Table I

Primers for reverse transcription-quantitative polymerase chain reaction.

Gene symbolPrimers
β-actin F-5′-AGCAGAGAATGGAAGAGTAAA-3′
R-5′-ATGCTGCTTACATGTCTCGAT-3′
CLDN4 F-5′-TATGGATGAACTGCGTGGTG-3′
R-5′-GATGATGVTGATGATGACGAG-3′
CLDN1 F-5′-GAAGTGTATGAAGTGCTTGG-3′
R-5′-GGGTCATAGGGTCATAGAAT-3′
CLDN2 F-5′-GTGAAGGCAGAGATGAGAAGAGG-3′
R-5′-ATGGGATTTGGGCTTTTGG-3′
FLG F-5′-AGACTGGGAGGCAAGCTACAAC-3′
R-5′-TGGTTTGGAGTGGGATTGCT-3′

[i] F, forward; R, reverse; CLDN, Claudin; FLG, filaggrin.

Western blotting

ATRA-treated and untreated HaCaT cells were lysed in radioimmunoprecipitation assay buffer [150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 0.5% deoxycholate, 0.1% SDS, 1% Nonidet P-40 and protease inhibitor cocktail; Sigma-Aldrich; Merck KGaA] at 4°C for 1 h. Protein concentration was measured using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts of proteins (30 µg) were separated on 12% SDS-PAGE gels and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA). TBS buffer containing Tween-20 (TBST) and 5% non-fat milk was used to block non-specific binding at room temperature for 2 h. Following blocking, primary antibodies were incubated overnight at 4°C: Rabbit anti-human Claudin-1 (cat. no. 13050-1-AP; ProteinTech Group, Inc., Chicago, IL, USA; 1:200), goat anti-human Claudin-4 (cat. no. 17664; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; 1:200) and mouse anti-human β-actin (cat. no. 47778; Santa Cruz Biotechnology, Inc.; 1:1,000). The membranes were washed three times with TBST for 5 min. Horseradish peroxidase (HRP)-conjugated Affinipure Rabbit Anti-Goat IgG (H+L) (cat. no. SA00001-2; ProteinTech Group, Inc.; 1:3,000), HRP-conjugated Affinipure Goat Anti-Mouse IgG (H+L) (cat. no. SA00001-1; ProteinTech Group, Inc.; 1:3,000) and HRP-conjugated Affinipure Donkey Anti-Goat IgG (H+L) (cat. no. SA00001-3; ProteinTech Group, Inc.; 1:4,000) were incubated for 1 h at 37°C prior to visualization with enhanced chemiluminescence (Amersham; GE Healthcare). Densitometry was used to quantify the signal intensities using Quantity One 4.5 software (Bio-Rad Laboratories, Inc.). All measurements were performed in triplicates from three independent experiments.

Immunofluorescence

HaCaT cells and cryostat sections (4 µm) of skin from ATRA-treated and untreated mice were fixed in ice-cold 4% paraformaldehyde in PBS for 30 min. Non-specific binding was blocked with 10% normal goat serum (OriGene Technologies, Inc., Beijing, China) for 20 min at 37°C. Goat anti-human Claudin-4 (1:50) and rabbit anti-human Claudin-1 antibodies (1:50) were incubated overnight at 4°C. PBS was used as a negative control. The sections were washed twice for 5 min in PBS. Alexa Fluor 594-labeled secondary antibodies (cat. nos. A32758 and A32740; Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA; 1:200) were incubated for 1 h at room temperature and revealed using DAPI (1:5,000 in PBS) for 2 min at room temperature. A laser scanning confocal microscope (LSM510; Zeiss AG, Oberkochen, Germany) was used to capture images of the cells (×200 magnification).

Statistical analysis

All statistical analyses were conducted using SPSS 16.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as the mean ± standard deviation. All measurements were performed in triplicate from three independent experiments. The distribution was tested for normality using the Kolmogorov-Smirnov test. Statistical significance was evaluated by independent sample t-test for normally distributed data and using the Mann-Whitney U test for non-normally distributed data. P<0.05 was considered to indicate a statistically significant difference.

For the microarray data, the NimbleScan software (version 2.5; NimbleGen Systems, Inc.) was used to conduct grid alignment and analyze the expression profiles. The Robust Multichip Average (RMA) algorithm and quantile normalization in NimbleScan software were applied to the normalized expression data. The gene levels were inputted into the Agilent GeneSpring software (version 12.0; Agilent Technologies, Inc., Santa Clara, CA, USA). Fold-change filtering was applied for the identification of genes with differential expression levels. The threshold was set at-fold-change ≥2.0. The Agilent GeneSpring GX software (version 12.0; Agilent Technologies, Inc.) was used to conduct hierarchical clustering. The roles of the differentially expressed genes were determined using Gene Ontology (GO; www.geneontology.org) and pathway analyses (https://www.genome.jp/kegg) conducted on the basis of the standard enrichment computation method, and using Fisher’s exact test to determine whether the amount of overlaps between the GO annotation list and the list of differentially expressed genes was significant. P≤0.05 indicated that the GO term enrichment was statistically significant.

Results

Topical ATRA induces histological alterations in the skin of treated mice

After 5 days of treatment, no marked alterations were detected in the control skin. Circumscribed erythema occurred after 3 days of ATRA application (n=6), with fine flat scales covering the surface of the erythema that peaked at 5 days (Fig. 1). Hematoxylin and eosin staining of ATRA-treated skin demonstrated crust, focal parakeratosis, hyperproliferation and intercellular edema of the stratum spinosum (Fig. 2A). In the ATRA-treated dermis, large amounts of inflammatory cell infiltration and capillary dilation were observed (Fig. 2A). Epidermal thickness was 2.5 times higher following ATRA intervention compared with that of the control group (P<0.0001), in addition to increases in parakeratosis (P<0.001) and spongiosis (P<0.002). In the dermis, perivascular lymphocytic infiltration (P<0.002) and telangiectasia (P<0.002) were observed in the dermal papilla and in the superficial layer (Fig. 2B).

ATRA treatment causes ultrastructural abnormalities in the epidermis

Compared with control skin, keratohyalin granules were decreased in number in the SG (n=3; Fig. 3A). TEM also demonstrated that the keratinocyte cytoskeleton was damaged by ATRA and that the cytoskeletal network disappeared in the local upper stratum corneum (Fig. 3A). In the upper stratum corneum, multiple lipid droplets were observed in the cytoplasm of corneocytes in the ATRA-treated skin (Fig. 3B). In the epidermis of ATRA-treated skin, TEM revealed a disordered arrangement of stratum spinosum cells, in addition to the appearance of significantly larger nucleoli and wider intercellular spaces (Fig. 3B). Desmosomes were decreased and disordered in ATRA-treated skin (Fig. 3C). Quantitative analysis of keratohyalin granules, lipid droplets and desmosomes is presented in Fig. 3D.

Gene expression profiling reveals dysregulation of epidermal barrier-associated genes in the mouse epidermis and HaCaT cells treated with ATRA

With the aim of improving the understanding of the molecular mechanisms of ATRA-induced barrier dysfunction, gene expression array analysis (n=1) was used to identify candidate genes for barrier function in the mouse skin and HaCaT cells. There were 897 upregulated and 1,087 downregulated genes following treatment with ATRA in the mouse epidermis. Similarly, there were 1,220 upregulated and 905 downregulated genes following treatment with ATRA in HaCaT cells. The genes involved in epidermal barrier function were revealed by gene expression analyses and are presented in Tables IITable IIITable IVV. The downregulated epidermal barrier-associated genes following treatment with ATRA in the mouse skin included genes involved in ‘cornified envelope components’, ‘intermediate filament’, ‘lipid metabolic process’, ‘gap junction’, ‘tight junction’ and ‘desmosome’ (Table II). The upregulated epidermal barrier-associated genes following treatment with ATRA in mouse skin included genes involved in ‘cornified envelope components’, ‘serine protease and protease inhibitors’, ‘lipid metabolic process’, ‘tight junction’ and ‘transcriptional factors’ (Table III). The downregulated epidermal barrier-associated genes following treatment with ATRA in HaCaT cells included genes involved in ‘intermediate filament’, ‘proteases and protease inhibitors’ and ‘tight junction’ (Table IV). The upregulated epidermal barrier-associated genes following treatment with ATRA in HaCaT cells included genes involved in ‘intermediate filament’, ‘proteases and protease inhibitors’ and ‘tight junction’ (Table V).

Table II

Downregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in mouse skin (n=1 per group;-fold change >2; P<0.05).

Table II

Downregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in mouse skin (n=1 per group;-fold change >2; P<0.05).

A, Cornified envelope components
GenBank accession no.Gene nameGene full nameFold downregulation
AF510860FLGFilagrin2.13
BC108980FOXN1Forkhead box N12.42
BC107019SPRR4Small proline-rich protein 42.67
BC109181LCE1MLate cornified envelope 1M6.64
BC031486PPHLN1Periphilin 12.40
BC119192GPRC5DProtein-coupled receptor, class C, group 5, member D20.66

B, Intermediate filament

GenBank accession no.Gene nameGene full nameFold downregulation

BC003472KRT23Keratin 232.67
BC129847KRT24Keratin 242.66
BC018391KRT25Keratin 256.56
BC116672KRT26Keratin 267.78
AB288231KRT28Keratin 284.28
BC117553KRT32Keratin 326.04
BC12542KRT34Keratin 34101.08
BC100542KRT35Keratin 356.86
BC119521KRT40Keratin 4010.11
BC125346KRT71Keratin 712.90
BC067067KRT73Keratin 734.34
BC107395KRT77Keratin 779.12
BC119366KRT80Keratin 802.21
AF312018KRT81Keratin 8130.65
BC10897KRT82Keratin 8210.18
BC152922KRT85Keratin 8519.46
BC029257KRT33AKeratin associated protein 33A39.26
NM_013570KRT33BKeratin associated protein 33B4.79
NM_001085526KRTAP1-2Keratin associated protein 1-313.42
XM_894811KRTAP3-1Keratin associated protein 3-129.03
BC156698KRTAP4-2Keratin associated protein 4-219.09
NM_026834KRTAP4-6Keratin associated protein 4-624.72
BC115508KRTAP4-7Keratin associated protein 4-733.02
NM_001085547KRTAP4-8Keratin associated protein 4-843.14
NM_001085548KRTAP4-9Keratin associated protein 4-924.62
BC016249KRTAP4-16Keratin associated protein 4-1642.20
NM_015809KRTAP5-4Keratin associated protein 5-419.54
NM_027771KRTAP7-1Keratin associated protein 7-1137.50
AK133727KRTAP8-1Keratin associated protein 8-118.92
BC116210KRTAP9-1Keratin associated protein 9-111.56
BC156686KRTAP9-3Keratin associated protein 9-335.46
NM_001085527KRTAP9-5Keratin associated protein 9-512.10
BC116219KRTAP15Keratin associated protein 1560.31
BC116200KRTAP19-4Keratin associated protein 19-410.75
BC115545KRTAP19-3Keratin associated protein 19-38.54
BC132612KRTAP6-5Keratin associated protein 6-514.96
BC132658KRTAP16-3Keratin associated protein 16-339.91
BC128283KRTAP26-1Keratin associated protein 26-16.51

C, Lipid metabolic process

GenBank accession no.Gene nameGene full nameFold downregulation

AK003689LYPLA2Lysophospholipase II2.00
BC027524PLA2G2EPhospholipase A2, group IIE2.60
BC148434PLCH2Phospholipase C eta 22.13
BC047281AGPAT4 1-acylglycerol-3-phosphate O-acyltransferase 43.81
BC031987AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 53.17
AK019476SMPD3Sphingomyelin Phosphodiesterase 3 neutral2.15
AK088962SMPD2Sphingomyelin phosphodiesterase 2 neutral2.10
BC013751ALOX12EArachidonate lipoxygenase3.90
BC043059LASS5/Cers5Epidermal ceramide synthase 52.82
BC075627DGKKDiacylglycerol kinase κ3.89
BC021597APOMApolipoprotein M2.58
BC006863FAAHFatty acid amide hydrolase2.22
BC071266FADS3Fatty acid desaturase 32.53

D, Gap junction

GenBank accession no.Gene nameGene full nameFold downregulation

AY427554GJA1Gap junction protein α12.00
AY390399GJA3Gap junction protein α32.57
BC024387GJB3Gap junction protein β32.77

E, Tight junction

GenBank accession no.Gene nameGene full nameFold downregulation

AK165750PRKCZProtein kinase C ζ2.37
DQ682659MARVELD2MARVEL domain containing 23.81
AK190015TJAP1Tight junction associated protein 12.08
BC049662MPP7Membrane palmitoylated protein 72.11

F, Desmosome

GenBank accession no.Gene nameGene full nameFold downregulation

BC020144DSG2Desmoglein 24.48

Table III

Upregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in the mouse skin (n=1 per group;-fold change >2; P<0.05).

Table III

Upregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in the mouse skin (n=1 per group;-fold change >2; P<0.05).

A, Cornified envelope components
GenBank accession no.Gene nameGene full nameFold upregulation
BC115788LCE3BLate cornified envelope 3B3.17
BC119239LCE3CLate cornified envelope 3C5.35
BC125542SPRR2JSmall proline-rich protein 2J2.38
BC130233SPRR2GSmall proline-rich protein 2G3.57
BC078629S100A8S100 calcium binding protein A8 (calgranulin A)3.31
AK143826S100A9S100 calcium binding protein A9 (calgranulin B)3.81

B, Serine protease and protease inhibitors

GenBank accession no.Gene nameGene full nameFold upregulation

BC031119KLK6Kallikrein related-peptidase 63.22
BC002100KLK10Kallikrein related-peptidase 102.90
XM_893506KLK12Kallikrein related-peptidase 122.50
BC054091SERPINE1Serine (cysteine) proteinase inhibitor, clade E, member 12.15
BC010675SERPINE2Serine (cysteine) proteinase inhibitor, clade E, member 22.98

C, Lipid metabolic process

GenBank accession no.Gene nameGene full nameFold upregulation

BC010829ACNAT2Acyl-coenzyme A amino acid N-acyltransferase 22.03
DQ469311ACNAT1Acyl-coenzyme A amino acid N-acyltransferase 12.94
AK171255ACOT11Acyl-CoA thioesterase 113.73
BC050828UGCGUDP-glucose ceramide glucosyltransferase2.21
BC060600PLA2G4EPhospholipase A2, group IVE2.39
BC003470PLA1APhospholipase A1 member A2.06
BC003943DPAGT1Dolichyl-phosphate (UDP-N-acetylglucosamine) glycerol2.10

D, Tight junction

GenBank accession no.Gene nameGene full nameFold upregulation

BC015252CLDN2 Claudin-22.43

E, Transcriptional factors

GenBank accession no.Gene nameGene full nameFold upregulation

BC070398PPARδPeroxisome proliferator activator receptor δ2.00

Table IV

Downregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in HaCaT cells (n=1 per group;-fold change >2; P<0.05).

Table IV

Downregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in HaCaT cells (n=1 per group;-fold change >2; P<0.05).

A, Intermediate filament
GenBank accession no.Gene nameGene full nameFold downregulation
NM_181619KRTAP21-1Keratin associated protein 21-12.38
NM_033448KRT71Keratin 712.00
BC024292KRT5Keratin 52.22

B, Proteases and protease inhibitors

GenBank accession no.Gene nameGene full nameFold downregulation

BC069417SERPINB7Serpin family B member 73.15
NM_000185SERPIND1Serpin family D member 12.36
NM_007173PRSS23Serine protease 234.13
NM_022046KLK14Kallikrein related peptidase 102.29

C, Tight junction

GenBank accession no.Gene nameGene full nameFold downregulation

AK128686PDZD2PDZ domain containing 22.15

Table V

Upregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in HaCaT cells (n=1 per group;-fold change >2; P<0.05).

Table V

Upregulation of epidermal barrier-associated genes following treatment with all-trans retinoic acid in HaCaT cells (n=1 per group;-fold change >2; P<0.05).

A, Intermediate filament
GenBank accession no.Gene nameGene full nameFold upregulation
NM_002275KRT15Keratin 152.07
BC072018KRT17Keratin 172.68
AB096945KRTAP19-4Keratin associated protein 19-42.07
BC101555KRTAP7-1Keratin associated protein 7-1 (gene/pseudogene)2.05
NM_032524KRTAP4-4Keratin associated protein 4-42.16

B, Proteases and protease inhibitors

GenBank accession no.Gene nameGene full nameFold upregulation

NM_001085SERPINA3Serpin family A member 312.30
NM_000624SERPINA5Serpin family A member 52.03
BC034528SERPINB8Serpin family B member 82.11
NM_000934SERPINF2Serpin family F member 22.06
NM_002575SERPINB2Serpin family B member 22.17
BC009726PRSS22Serine protease 224.26
AF335478KLK3Kallikrein related peptidase 32.27
NM_001012964KLK6Kallikrein related peptidase 62.95
NM_002776KLK10Kallikrein related peptidase 102.44
NM_006853KLK11Kallikrein related peptidase 112.43
NM_015596KLK13Kallikrein related peptidase 132.80
NM_017509KLK15Kallikrein related peptidase 152.02

C, Tight junction

GenBank accession no.Gene nameGene full nameFold upregulation

BC029886OCLN Occludin2.63
NM_001305CLDN4 Claudin-42.02

The pathway analyses demonstrated that differentially expressed genes were significantly associated with AJs, TJs and focal adhesion in ATRA-treated epidermal tissues. The top ten pathways of up- and downregulated differentially expressed genes are presented in Fig. 4A and B, respectively. The top ten three GO-fold enrichment of differentially expressed genes revealed significant downregulation of epidermal barrier function-associated processes, including ‘regulation of keratinocyte differentiation’, ‘keratin filament’ and ‘gap junction’ channel activity (Fig. 4C-H). In ATRA-treated epidermal tissues, a series of dysregulated genes associated with the epidermal differentiation complex (EDC) were observed, which included small proline-rich region proteins (SPRRs), filaggrin (FLG), loricrin (LOR) and the S100 gene family. These proteins are essential for the formation of the cell envelope during terminal differentiation. A number of these genes were members of the SPRR family: SPRR4 (−2.67-fold), SPRR2J (+2.38-fold) and SPRR2G (+3.57-fold). The remainder were part of the S100 gene family: S100A8 (+3.31-fold) S100A9 (+3.81-fold) and FLG (−2.13-fold) (Tables II and III). During keratinocyte differentiation, the late cornified envelope protein (LCE) was induced and had similar functions to the functions of the SPRR family (cross-linking proteins) in the CE. LCE1M (6.64-fold) was downregulated, while LCE3C (5.35-fold) and LCE3B (3.17-fold) were upregulated (Tables II and III). Nevertheless, no notable abnormalities were observed in the above genes in HaCaT cells. In ATRA-treated epidermal tissues and HaCaT cells, marked dysregulation of numerous keratins and keratin-associated proteins was observed, suggesting abnormal terminal differentiation of keratinocytes upon ATRA treatment. Serine proteases and serine protease inhibitors are involved in the differentiation of keratinocytes and desquamation (24). In ATRA-treated epidermal tissues and HaCaT cells, the differential expression of serine proteases and serine protease inhibitors was observed. Among them, it was observed that KLK6 and KLK10 were consistently expressed in the mouse chip and HaCaT cells, and all of them were upregulated.

Genes encoding enzymes associated with lipid metabolism were demonstrated to be induced by ATRA in the mouse epidermis. Compared with the cells, the mice exhibited significant downregulation of a subset of enzymes associated with ceramide, free fatty acids and phospholipid synthesis: i) Sphingomyelin phosphodiesterase 3 (SMPD3; -2.15-fold) and sphingomyelin phosphodiesterase 2 (SMPD2, -2.10-folds), which catalyze the conversion of sphingolipids to ceramides; ii) epidermal ceramide synthase 5 (LASS5/Cers5; -2.82-fold), which catalyzes the synthesis of ceramides; iii) lysophospholipase II (LYPLA; -2.00-fold), phospholipase A2 group IIE2 (PLA2G2E; -2.60-fold), and phospholipase C eta 2 (PLCH2; -2.13-fold), which catalyze free fatty acid formation from phospholipids; and iv) 1-acylglycerol-3-phosphate O-acyltransferase 4 (AGPAT4; -3.81-fold) and 1-acylglyc-erol-3-phosphate O-acyltransferase 5 (AGPAT5; -3.17-fold), which catalyze the acylation of lysophosphatidic acid into phosphatidic acid. The latter is the primary precursor of all types of glycerolipids. Furthermore, arachidonate lipoxygenase (ALOX12E; a member of the epidermis-type LOX family that catalyzes the conversion of polyunsaturated fatty acids into oxygenated products) was downregulated by ATRA. Conversely, the present results also demonstrated upregulation of different isoforms of the aforementioned enzymes (Table III).

The dysregulation of numerous cell-cell junction-associated genes was observed in ATRA-treated mouse skin. Among these genes were components of TJs (TJAP1, MPP7, MARVELD2 and CLDN2), gap junctions (GJA, GJA and GJB4) and desmosomes (DSG2). Compared with the mouse skin specimens, only the TJ protein molecules Claudin-4 and occludin were upregulated in the cells.

ATRA treatment alters the expression and localization of TJs in HaCaT cells

In ATRA-treated cells, CLDN1 was downregulated 0.66-fold, while CLDN4, TJP3 and GJB4 were upregulated 1.82-, 3.63- and 1.92-fold (Fig. 5A). In mice treated with ATRA, CLDN1 (0.8-fold) and FLG (0.61-fold) were downregulated, while CLDN4 (1.47-fold) and CLDN2 (2.49-fold) were upregulated (Fig. 5B). Western blot analysis of CLDN4 and CLDN1 revealed similar results to those of the RT-qPCR (Fig. 5C).

Immunofluorescence revealed that the intensity of Claudin-1 was not only reduced at the cell-cell contact areas, but also appeared to be discontinuous along the cell membranes of HaCaT cells treated with ATRA (Fig. 6). However, Claudin-4 staining was slightly increased and displayed a string-like localization pattern (Fig. 6).

ATRA alters the expression and localization of TJs in mouse epidermis

A marked reduction in the staining intensity and localization of Claudin-1 in the upper epidermal layer of skin treated with ATRA was discovered compared with control skin (n=3; Fig. 7). By contrast, Claudin-4 staining was stronger in the ATRA-treated skin compared with control skin (Fig. 7).

Discussion

In the present study, the ATRA-associated dermatitis animal model presented erythema, scaling and dryness of the treated skin, similar to the irritation observed in ATRA-treated human skin (25,26), indicating that this animal model is a useful tool to evaluate the effectiveness and side effects of ATRA. Furthermore, treatment with ATRA altered the normal morphology and ultrastructure of the mouse epidermis. Microarray analysis was used, primarily to identify candidates that were later confirmed via RT-qPCR and/or immunohistochemistry.

In the mouse model of ATRA-stimulated dermatitis, the epidermis of the mice exhibited obvious scales, while histopathology revealed parakeratosis of the epidermis, suggesting that the epidermal differentiation was abnormal, and that the abnormal differentiation of keratinocytes led to an epidermal keratinization envelope. In the mouse gene expression profiles, it was observed that the majority of alterations occurred among EDC genes, including FLG, SPRR4, SPRR2J, SPRR2G, LCE3C, LCE3B, LCE1M, S100A8 and S100A9. The proteins encoded by those genes, together with LOR, involucrin, trichohyalin and hornerin, are associated with CE generation via crosslinking of insoluble membranous proteins (27). Keratinized proteins act as markers of differentiation in the epidermis. In the mice and cells, the abnormal expression of keratins, including KRT15, KRT17 and KRT14, and keratin-associated proteins, including KRT33A, KRT33A and KRTAP1-3, was widely observed, further confirming the abnormal terminal differentiation in the epidermis following ATRA treatment.

Proteases, together with their inhibitors and targets, serve an essential role in desquamation (24). In the ATRA-treated mouse epidermis and HaCaT cells, the upregulation of tissue kallikreins (KLK6, KLK10, KLK12 and KLK14) and protease inhibitors (SERPINE 1 and SERPINE 2) was demonstrated. It is noteworthy that KLK6 and KLK10 were upregulated in mice and cells following ATRA treatment, which may be closely associated with the appearance of scales on the mouse skin. Furthermore, alterations in the balance between proteases and protease inhibitors in the skin lead to inflammatory reactions, which causes itching, scaling, redness and other typical clinical symptoms (28).

Morphologically, the appearance of profilaggrin is consistent with the formation of keratohyalin granules. The newly-synthesized profilaggrin accumulates in keratohyalin granules with high phosphoric acid and histidine following phosphorylation. The present study demonstrated that the number of keratohyalin granules decreased significantly following ATRA treatment. Therefore, it was speculated that decreases in the number of keratohyalin granules may affect the phosphorylation and accumulation of newly-synthesized profilaggrin, affecting the production of FLG. In addition, a number of factors that are important in controlling FLG expression have been described, such as transcription factors of the AP1 family (Jun and/or Fos), POU-domain proteins, transcription factor p63, and the peroxisome-proliferator-activated-receptor (PPAR) family (29). Aberrant profilaggrin processing has also been observed in 12R-lipoxygenase (12R-LOX)-deficient mice (30). In the present study, the gene chip results revealed that PPAR was upregulated and ALOX12E was downregulated following ATRA treatment. As expected, the gene chip analysis and RT-qPCR revealed that the expression of FLG was downregulated following ATRA treatment in the mouse skin, as supported by Sybert et al (31), who reported that patients with ichthyosis vulgaris displayed a reduction or absence of profilaggrin and FLG along with a morphological reduction in the amount of keratohyalin. Filaggrin is also involved in the production of primary natural moisturizing factors in the stratum corneum (29). Whether these alterations in expression may affect the expression of FLG and the specific regulatory mechanism requires further investigation.

Following ATRA treatment, alterations in the ultrastructure of the epidermis were observed under an electron microscope. The images revealed that there were numerous circular vacuolated structures in the stratum corneum, which were similar to the ultrastructure of lipid droplets. Ponec et al (32) studied the lipid and ultrastructure of reconstructed skin models by electron microscopy. Their results indicated that lipid droplets in keratinocytes appeared in all three skin models, but the extent of the lipid droplets varied. The structure of the lipid droplets in their images was consistent with the structure of lipid droplets observed under electron microscopy in the present study. It was also thought that the different levels of lipid droplets in keratinocytes were associated with the hyperproliferative state of reconstructed skin. On the other hand, the epidermal layers of the mice in the present study were increased following ATRA treatment, indicating that there was a degree of proliferation. Therefore, it was speculated that these structures may be lipid droplets. Nevertheless, this is a limitation of the present study.

The ATRA-treated mouse skin displayed a large number of lipid droplets in certain corneocytes [similar in appearance to the droplets observed by Ponec et al (32)], suggesting that lipid metabolism was abnormal. Gene expression analysis of skin samples from ATRA-treated and control skin demonstrated significant induction of functional proteins associated ceramide, non-esterified fatty acids and phospholipid synthesis. The present study revealed down-regulation of SMPD3, SMPD2 and LASS5/Cers5, which catalyze the synthesis of ceramides, suggesting decreased ceramide synthesis in ATRA-treated mice. Conversely, it was observed that ATRA also increased the expression of UDP-glucose ceramide glucosyltransferase (UGCG). Moreover, Amen et al (33) reported that mice with deficiencies in UGCG display an ichthyosis-like skin phenotype and impairment in the differentiation of keratinocytes, which is associated with delayed wound healing.

Mao-Qiang et al (34) demonstrated that inhibiting PLA2 resulted in a defective extracellular lipid membrane and impaired homeostasis in the permeability barrier (34). In the present study, ATRA not only downregulated PLA2G2E and other phospholipases including PLCH2, but also upregulated PLA2G4E, LYPLA and DEG. Lu et al (35) demonstrated that the transcription levels of AGPAT-1, -2 and -3 were rapidly increased by ATRA. The present gene expression analysis of ATRA-treated skin revealed a marked reduction in the levels of AGPAT4 and AGPAT5.

Previously, lipoxygenases (LOXs) were reported to exert essential roles in regulating epithelial proliferation and/or differentiation, maintaining the permeability barrier, skin inflammation and wound healing (36). In the present study, no marked alterations in the protein levels of eLOX-3 and 12R-LOX in ATRA-treated skin were detected, but ATRA-treatment significantly downregulated ALOX12E, which may have a role in regulating keratinocyte differentiation (37).

TEM analysis of the mouse skin revealed an increase in the intercellular space, suggesting that the keratinocytes of the mice may have had abnormalities in the TJs. TJs function as a paracellular barrier beneath the stratum corneum (38). In the present study, Claudin-1 was decreased, but Claudin-4 was increased following ATRA-treatment in HaCaT cells and the mouse epidermis. Claudin-1-knockout mice exhibit increased epidermal permeability, severe water loss and skin wrinkling, and succumb within 24 h after birth (17). Downregulation of Claudin-1 results in decreased transepithelial electrical resistance (39). In addition, patients with atopic dermatitis exhibit low levels of Claudin-1 expression (40). Nevertheless, a previous in vitro study of cultured keratinocytes uncovered barrier defects resulting from knocking down Claudin-4 (41). The present study revealed that the expression of Claudin-4 was increased following ATRA treatment in HaCaT cells and the mouse epidermis, as previously observed in the oral mucosa (14). Nevertheless, significant upregulation of Claudin-4 was observed in the non-lesional skin of patients with atopic dermatitis, which may indicate a compensatory response to disrupted barrier function caused by Claudin-1 downregulation that leads to the upregulation of other Claudins (18,42). Therefore, downregulated Claudin-1 and the alteration of its localization in HaCaT cells and the mouse epidermis was likely responsible, at least in part, for the observed disruption of TJ barrier function following ATRA treatment.

It was observed that Claudin-2 mRNA was upregulated 2.5-fold. Telgenhoff et al (43) studied the regulation of Claudin-2 mRNA and protein expression by ATRA in human keratinocytes, and discovered that ATRA increases the expression of Claudin-2 in keratinocytes in a dose-dependent manner. In addition, Claudin-2 is highly expressed in the TJs of mouse renal proximal tubules, which possess a leaky epithelium whose unique permeability properties underlie their high rate of NaCl reabsorption (43,44). On the other hand, the Cldn2-KO mice display a normal appearance, activity, growth and behavior, with no abnormalities in the epidermal barrier (44); therefore, it was not included in the present study as a candidate gene due to funding limitations, but it may be considered in future studies.

Notably, certain differences were observed between the in vivo and the in vitro experiments. The possible causes include the following: i) HaCaT cells are human-derived immortalized keratin-forming cells, while the skin tissues were derived from mice, thus the two are different in species; ii) cells growing in vitro and in vivo are not completely analogous; and iii) the doses of ATRA in vivo and in vitro were different. In addition, the present study is limited since it focused primarily on Claudin-1 and -4, and additional studies are required to assess the exact contribution to ATRA-induced dermatitis of all the identified differentially expressed genes. The microarray experiment would ideally have been performed in multiple samples, but research funding was very limited; thus, there was only one sample per group, which is a limitation. Nevertheless, the microarray experiment only provides an idea of the potential genes that may be examined in future studies. Subsequent experiments in vivo and in vitro will be performed to confirm the results.

In conclusion, the results suggest that ATRA disrupts the normal morphology and ultrastructure of the mouse epidermis and exerts an essential role in the function of the epidermal barrier. Gene expression analyses revealed numerous dysregulated genes associated with the synthesis/generation of transcription factors, protease inhibitors, proteases, junctional proteins, lipids, corneocytes and cornified envelopes. ATRA not only alters the expression of Claudin-1 and -4, but also alters their localization in HaCaT cells and the murine epidermis. ATRA exerts a dual effect on epidermal barrier genes: It downregulates the expression of Claudin-1 and upregulates the expression of Claudin-4. Claudin-4 upregulation may be a compensatory response for the disrupted barrier function caused by Claudin-1 downregulation.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81171490) and the Fundamental Research Funds for the Central Universities (grant no. PY3A0241001016).

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the GEO repository (GSE124183): https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124183.

Authors’ contributions

SG and JL designed the experiments. JL conducted the experiments, performed the statistical analysis and drafted the manuscript. QL performed the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All experimental procedures were performed in accordance with the ‘Principles of Laboratory Animal Care’ (National Institutes of Health) and the guidelines of the laboratory animal care committee of Xi’an Jiaotong University (no. XJTULAC2017-733).

Patient consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Acknowledgments

Not applicable.

Abbreviations:

ATRA

all-trans retinoic acid

TEM

transmission electron microscopy

TJs

tight junctions

GO

Gene Ontology

DMSO

dimethyl sulfoxide

EDC

epidermal differentiation complex

SPRRs

small proline-rich region proteins

FLG

filaggrin

LOR

loricrin

References

1 

Ahuja HS, Szanto A, Nagy L and Davies PJ: The retinoid X receptor and its ligands: Versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul Homeost Agents. 17:29–45. 2003.PubMed/NCBI

2 

Wilson L, Gale E and Maden M: The role of retinoic acid in the morphogenesis of the neural tube. J Anat. 203:357–368. 2003. View Article : Google Scholar : PubMed/NCBI

3 

Thielitz A and Gollnick H: Topical retinoids in acne vulgaris: Update on efficacy and safety. Am J Clin Dermatol. 9:369–381. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Torma H, Bergström A, Ghiasifarahani G and Berne B: The effect of two endogenous retinoids on the mRNA expression profile in human primary keratinocytes, focusing on genes causing autosomal recessive congenital ichthyosis. Arch Dermatol Res. 306:739–747. 2014. View Article : Google Scholar : PubMed/NCBI

5 

Zhang ML, Tao Y, Zhou WQ, Ma PC, Cao YP, He CD, Wei J and Li LJ: All-trans retinoic acid induces cell-cycle arrest in human cutaneous squamous carcinoma cells by inhibiting the mitogen-activated protein kinase-activated protein 1 pathway. Clin Exp Dermatol. 39:354–360. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Ale SI, Laugier JP and Maibach HI: Differential irritant skin responses to tandem application of topical retinoic acid and sodium lauryl sulphate: Ii. Effect of time between first and second exposure. Br J Dermatol. 137:226–233. 1997. View Article : Google Scholar : PubMed/NCBI

7 

Kirschner N, Houdek P, Fromm M, Moll I and Brandner JM: Tight junctions form a barrier in human epidermis. Eur J Cell Biol. 89:839–842. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Brandner JM: Importance of tight junctions in relation to skin barrier function. Curr Probl Dermatol. 49:27–37. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Furuse M, Sasaki H, Fujimoto K and Tsukita S: A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol. 143:391–401. 1998. View Article : Google Scholar : PubMed/NCBI

10 

Furuse M and Tsukita S: Claudins in occluding junctions of humans and flies. Trends Cell Biol. 16:181–188. 2006. View Article : Google Scholar : PubMed/NCBI

11 

Turksen K and Troy TC: Permeability barrier dysfunction in transgenic mice overexpressing claudin 6. Development. 129:1775–1784. 2002.PubMed/NCBI

12 

Troy TC, Rahbar R, Arabzadeh A, Cheung RM and Turksen K: Delayed epidermal permeability barrier formation and hair follicle aberrations in inv-cldn6 mice. Mech Dev. 122:805–819. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Sugawara T, Iwamoto N, Akashi M, Kojima T, Hisatsune J, Sugai M and Furuse M: Tight junction dysfunction in the stratum granulosum leads to aberrant stratum corneum barrier function in claudin-1-deficient mice. J Dermatol Sci. 70:12–18. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Hatakeyama S, Ishida K and Takeda Y: Changes in cell characteristics due to retinoic acid; specifically, a decrease in the expression of claudin-1 and increase in claudin-4 within tight junctions in stratified oral keratinocytes. J Periodontal Res. 45:207–215. 2010. View Article : Google Scholar

15 

Anderson JM and Van Itallie CM: Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 1:a0025842009. View Article : Google Scholar :

16 

Furuse M: Knockout animals and natural mutations as experimental and diagnostic tool for studying tight junction functions in vivo. Biochim Biophys Acta. 1788:813–819. 2009. View Article : Google Scholar

17 

Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A and Tsukita S: Claudin-based tight junctions are crucial for the mammalian epidermal barrier: A lesson from claudin-1-deficient mice. J Cell Biol. 156:1099–1111. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Gruber R, Börnchen C, Rose K, Daubmann A, Volksdorf T, Wladykowski E, Vidal-Y-Sy S, Peters EM, Danso M, Bouwstra JA, et al: Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. Am J Pathol. 185:2777–2789. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Tokumasu R, Yamaga K, Yamazaki Y, Murota H, Suzuki K, Tamura A, Bando K, Furuta Y, Katayama I and Tsukita S: Dose-dependent role of claudin-1 in vivo in orchestrating features of atopic dermatitis. Proc Natl Acad Sci USA. 113:E4061–E4068. 2016. View Article : Google Scholar : PubMed/NCBI

20 

Tokumasu R, Tamura A and Tsukita S: Time- and dose-dependent claudin contribution to biological functions: Lessons from claudin-1 in skin. Tissue Barriers. 5:e13361942017. View Article : Google Scholar : PubMed/NCBI

21 

Bożek A and Reich A: The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment. Adv Clin Exp Med. 26:851–856. 2017. View Article : Google Scholar

22 

Fisher G, Esmann J, Griffiths CE, Talwar HS, Duell EA, Hammerberg C, Elder JT, Finkel LJ, Karabin GD, Nickoloff BJ, et al: Cellular, immunologic and biochemical characterization of topical retinoic acid-treated human skin. J Invest Dermatol. 96:699–707. 1991. View Article : Google Scholar : PubMed/NCBI

23 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar

24 

Ovaere P, Lippens S, Vandenabeele P and Declercq W: The emerging roles of serine protease cascades in the epidermis. Trends Biochem Sci. 34:453–463. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Phillips TJ: An update on the safety and efficacy of topical retinoids. Cutis. 75:14–22. 24discussion 22–23. 2005.PubMed/NCBI

26 

Weiss JS, Shavin JS, Nighland M and Grossman R: Tretinoin microsphere gel 0.1% for photodamaged facial skin: A placebo-controlled trial. Cutis. 78:426–432. 2006.

27 

Marshall D, Hardman MJ, Nield KM and Byrne C: Differentially expressed late constituents of the epidermal cornified envelope. Proc Natl Acad Sci USA. 98:13031–13036. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Meyer-Hoffert U: Reddish, scaly, and itchy: How proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz). 57:345–354. 2009. View Article : Google Scholar

29 

Sandilands A, Sutherland C, Irvine AD and McLean WH: Filaggrin in the frontline: Role in skin barrier function and disease. J Cell Sci. 122:1285–1294. 2009. View Article : Google Scholar : PubMed/NCBI

30 

Epp N, Fürstenberger G, Muller K, de Juanes S, Leitges M, Hausser I, Thieme F, Liebisch G, Schmitz G and Krieg P: 12r-lipoxygenase deficiency disrupts epidermal barrier function. J Cell Biol. 177:173–182. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Sybert VP, Dale BA and Holbrook KA: Ichthyosis vulgaris: Identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol. 84:191–194. 1985. View Article : Google Scholar : PubMed/NCBI

32 

Ponec M, Boelsma E, Weerheim A, Mulder A, Bouwstra J and Mommaas M: Lipid and ultrastructural characterization of reconstructed skin models. Int J Pharm. 203:211–225. 2000. View Article : Google Scholar : PubMed/NCBI

33 

Amen N, Mathow D, Rabionet M, Sandhoff R, Langbein L, Gretz N, Jäckel C, Grone HJ and Jennemann R: Differentiation of epidermal keratinocytes is dependent on glucosylceramide: Ceramide processing. Hum Mol Genet. 22:4164–4179. 2013. View Article : Google Scholar : PubMed/NCBI

34 

Mao-Qiang M, Jain M, Feingold KR and Elias PM: Secretory phospholipase A2 activity is required for permeability barrier homeostasis. J Invest Dermatol. 106:57–63. 1996. View Article : Google Scholar : PubMed/NCBI

35 

Lu B, Jiang YJ, Man MQ, Brown B, Elias PM and Feingold KR: Expression and regulation of 1-acyl-sn-glycerol- 3-phosphate acyltransferases in the epidermis. J Lipid Res. 46:2448–2457. 2005. View Article : Google Scholar : PubMed/NCBI

36 

Krieg P and Fürstenberger G: The role of lipoxygenases in epidermis. Biochim Biophys Acta. 1841.390–400. 2014.

37 

Feingold KR: Thematic review series: Skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res. 48:2531–2546. 2007. View Article : Google Scholar : PubMed/NCBI

38 

Yuki T, Haratake A, Koishikawa H, Morita K, Miyachi Y and Inoue S: Tight junction proteins in keratinocytes: Localization and contribution to barrier function. Exp Dermatol. 16:324–330. 2007. View Article : Google Scholar : PubMed/NCBI

39 

Yamamoto T, Saeki Y, Kurasawa M, Kuroda S, Arase S and Sasaki H: Effect of RNA interference of tight junction-related molecules on intercellular barrier function in cultured human keratinocytes. Arch Dermatol Res. 300:517–524. 2008. View Article : Google Scholar : PubMed/NCBI

40 

De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, Berger AE, Zhang K, Vidyasagar S, Yoshida T, et al: Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 127:773–786. e1–7. 2011. View Article : Google Scholar

41 

Kirschner N, Rosenthal R, Furuse M, Moll I, Fromm M and Brandner JM: Contribution of tight junction proteins to ion, macromolecule, and water barrier in keratinocytes. J Invest Dermatol. 133:1161–1169. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Kubo T, Sugimoto K, Kojima T, Sawada N, Sato N and Ichimiya S: Tight junction protein claudin-4 is modulated via Δnp63 in human keratinocytes. Biochem Biophys Res Commun. 455:205–211. 2014. View Article : Google Scholar : PubMed/NCBI

43 

Telgenhoff D, Ramsay S, Hilz S, Slusarewicz P and Shroot B: Claudin 2 mRNA and protein are present in human keratinocytes and may be regulated by all-trans-retinoic acid. Skin Pharmacol Physiol. 21:211–217. 2008. View Article : Google Scholar : PubMed/NCBI

44 

Muto S, Hata M, Taniguchi J, Tsuruoka S, Moriwaki K, Saitou M, Furuse K, Sasaki H, Fujimura A, Imai M, et al: Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci USA. 107:8011–8016. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April-2019
Volume 43 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li J, Li Q and Geng S: All‑trans retinoic acid alters the expression of the tight junction proteins Claudin‑1 and ‑4 and epidermal barrier function‑associated genes in the epidermis Corrigendum in /10.3892/ijmm.2024.5399. Int J Mol Med 43: 1789-1805, 2019.
APA
Li, J., Li, Q., & Geng, S. (2019). All‑trans retinoic acid alters the expression of the tight junction proteins Claudin‑1 and ‑4 and epidermal barrier function‑associated genes in the epidermis Corrigendum in /10.3892/ijmm.2024.5399. International Journal of Molecular Medicine, 43, 1789-1805. https://doi.org/10.3892/ijmm.2019.4098
MLA
Li, J., Li, Q., Geng, S."All‑trans retinoic acid alters the expression of the tight junction proteins Claudin‑1 and ‑4 and epidermal barrier function‑associated genes in the epidermis Corrigendum in /10.3892/ijmm.2024.5399". International Journal of Molecular Medicine 43.4 (2019): 1789-1805.
Chicago
Li, J., Li, Q., Geng, S."All‑trans retinoic acid alters the expression of the tight junction proteins Claudin‑1 and ‑4 and epidermal barrier function‑associated genes in the epidermis Corrigendum in /10.3892/ijmm.2024.5399". International Journal of Molecular Medicine 43, no. 4 (2019): 1789-1805. https://doi.org/10.3892/ijmm.2019.4098